MicroRNA-210 overexpression predicts poorer prognosis in glioma patients.

MicroRNA-210 (miR-210) levels are elevated in many tumor types, are frequently associated with hypoxia induction, and are correlated with poor prognosis in many solid tumors. miR-210 regulates cell growth, angiogenesis, invasion, and apoptosis of many human tumors. In this study, we investigated the clinical significance of miR-210 expression in common brain tumors, or human gliomas. Glioma samples and normal brain tissues were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction to characterize the expression patterns of miR-210. The association of miR-210 expression with clinicopathological parameters and prognosis of glioma patients was statistically analyzed. Gliomas were further divided by grade: pilocytic astrocytoma (World Health Organization [WHO] grade I), diffuse astrocytomas (WHO grade II), anaplastic astrocytomas (WHO grade III), and glioblastoma (WHO grade IV). There was a significantly higher expression level of miR-210 amongst the glioma tissues as compared with normal brain tissues (p<0.001). Increased expression of miR-210 in glioma tissues was significantly associated with advanced pathological grade (p<0.001) and low Karnofsky Performance Score (p=0.014). In addition, increased miR-210 levels were also associated with poor progression-free survival (PFS) and overall survival (OS) rates when compared to the normal control (both p<0.001), as calculated by Kaplan-Meier survival and Cox regression analyses. Furthermore, subgroup analyses showed that miR-210 expression was significantly associated with poor PFS and OS of glioma patients with high pathological grades (III-IV: both p<0.001). miR-210 is highly expressed in human gliomas and confers a poor prognosis in glioma patients. These findings may bring the development of novel, tailored pharmacological therapies for glioma patients.

Lai NS ，Dong QS ，Ding H ，Miao ZL ，Lin YC ... -  《-》

Concomitant microRNA-31 downregulation and radixin upregulation predicts advanced tumor progression and unfavorable prognosis in patients with gliomas.

To clarify the clinical significance of microRNA-31 (miR-31) and radixin (RDX) in human glioma. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was used to characterize the expression patterns of miR-31 and RDX mRNA in 108 glioma and 20 normal brain tissues. The associations of miR-31 and RDX mRNA expressions with clinicopathologic factors and prognosis of glioma patients were also statistically analyzed. The expression levels of miR-31 in glioma tissues were significantly lower than those in normal brain tissues (P<0.001), while RDX mRNA was significantly overexpressed in glioma tissues compared with normal brain tissues (P<0.001). There was a negative correlation between miR-31 and RDX mRNA expression in glioma tissues (r=-0.69, P=0.01). Additionally, concomitant miR-31 downregulation and RDX upregulation (miR-31-low/RDX-high) was significantly associated with advanced pathological grade (P=0.001) and low Karnofsky performance score (P=0.01). Moreover, Kaplan-Meier survival and Cox regression analyses showed that the glioma patients with miR-31-low/RDX-high expression had poorest overall survival (P<0.001) and conjoined expression of miR-31-low/RDX-high was an independent prognostic indicator of glioma (P=0.01). Furthermore, subgroup analyses showed that miR-31-low/RDX-high expression was significantly associated with poor overall survival in glioma patients with high pathological grades (for grade III-IV: P<0.001). Our findings have implications concerning the importance of concomitant miR-31 downregulation and RDX upregulation in tumor progression and poor prognosis of patients with gliomas. A combined detection of miR-31/RDX expression may benefit us in predicting clinical outcomes of glioma patients with high pathological grades.

Wang S ，Jiao B ，Geng S ，Song J ，Liang Z ，Lu S ... -  《-》

MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma.

MicroRNA-203 (miR-203) serves as a tumor suppressor or a tumor promoter in different human malignancies. However, its involvement in human gliomas is still unclear. The aim of this study was to investigate the clinical significance of miR-203 expression in gliomas. Real-time quantitative PCR was employed to measure the expression level of miR-203 in clinical glioma tissues. The expression of miR-203 was reduced in high WHO grade glioma tissues compared with that in low WHO grade and normal brain tissues, and decreased with ascending tumor WHO grades (P < 0.001). The reduced miR-203 expression in gliomas was significantly associated with higher WHO grade (P < 0.001), lower KPS score (P = 0.008) and poorer disease-specific survival of patients (P = 0.001). More importantly, subgroup analyses according to tumor WHO grade revealed that the disease-specific survival of patients with low miR-203 expression in high WHO grades (III-IV) subgroup was significantly shorter than those with high miR-203 expression (P < 0.001), but no significant difference was found for patients in WHO grades I-II subgroup (P = 0.08). Our data validate an important clinical significance of miR-203 in gliomas, and reveal that it might be an intrinsic regulator of tumor progression and a potential prognostic factor for this dismal disease.

He J ，Deng Y ，Yang G ，Xie W ... -  《-》

Overexpression of microRNA-155 predicts poor prognosis in glioma patients.

Sun J ，Shi H ，Lai N ，Liao K ，Zhang S ，Lu X ... -  《-》

Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.

Yue X ，Lan F ，Hu M ，Pan Q ，Wang Q ，Wang J ... -  《-》